Search Results - "Oakervee, Heather E."

Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up by Popat, Rakesh, Oakervee, Heather E., Hallam, Simon, Curry, Nicola, Odeh, Liz, Foot, Nicola, Esseltine, Dixie‐Lee, Drake, Mary, Morris, Curly, Cavenagh, Jamie D.

“…Summary Bortezomib, doxorubicin and dexamethasone (PAD) was evaluated as induction before stem cell transplantation in newly diagnosed multiple myeloma (MM)…”
Get full text

Differential and tumor-specific expression of CD160 in B-cell malignancies by Farren, Timothy W., Giustiniani, Jerome, Liu, Feng-Ting, Tsitsikas, Dimitris A., Macey, Marion G., Cavenagh, James D., Oakervee, Heather E., Taussig, David, Newland, Adrian C., Calaminici, Maria, Bensussan, Armand, Jenner, Michael, Gribben, John G., Agrawal, Samir G.

“…CD160 is a human natural killer (NK)-cell–activating receptor that is also expressed on T-cell subsets. In the present study, we examined 811 consecutive cases…”
Get full text

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3 by Tornatore, Laura, Capece, Daria, D'Andrea, Daniel, Begalli, Federica, Verzella, Daniela, Bennett, Jason, Acton, Gary, Campbell, Elizabeth A., Kelly, James, Tarbit, Michael, Adams, Nigel, Bannoo, Selina, Leonardi, Antonio, Sandomenico, Annamaria, Raimondo, Domenico, Ruvo, Menotti, Chambery, Angela, Oblak, Metod, Al-Obaidi, Magda J., Kaczmarski, Richard S., Gabriel, Ian, Oakervee, Heather E., Kaiser, Martin F., Wechalekar, Ashutosh, Benjamin, Reuben, Apperley, Jane F., Auner, Holger W., Franzoso, Guido

“…[Display omitted] •DTP3 eliminates any viable MM cells in mice upon i.v. bolus administration.•DTP3 exhibits highly favourable PK and ADME profiles, with long…”
Get full text

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma by Morris, Treen Carson Michael, Drake, Mary B., Kettle, Paul J., McGuigan, Tracey, Leahy, Maeve, O’Dwyer, Michael, Enright, Helen, O’Shea, Tanya, Popat, Rakesh, Oakervee, Heather E., Yong, Kwee, Cavenagh, Jamie D., Cairns, David A., Alvarez-Iglesias, Alberto, Cook, Gordon

“…When the bortezomib [PS341], adriamycin and dexamethasone (PAD) regimen was first evaluated, the response rate in untreated patients was much superior to that…”
Get full text

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma by Spicka, Ivan, Ocio, Enrique M., Oakervee, Heather E., Greil, Richard, Banh, Raymond H., Huang, Shang-Yi, D’Rozario, James M., Dimopoulos, Meletios A., Martínez, Sara, Extremera, Sonia, Kahatt, Carmen, Alfaro, Vicente, Carella, Angelo M., Meuleman, Nathalie, Hájek, Roman, Symeonidis, Argiris, Min, Chang-Ki, Cannell, Paul, Ludwig, Heinz, Sonneveld, Pieter, Mateos, María Victoria

“…The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma…”
Get full text

PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma by Oakervee, Heather E., Popat, Rakesh, Curry, Nicola, Smith, Pat, Morris, Curly, Drake, Mary, Agrawal, Samir, Stec, Jim, Schenkein, David, Esseltine, Dixie‐Lee, Cavenagh, Jamie D.

“…Summary Bortezomib (formerly PS‐341) has significant activity in patients with relapsed multiple myeloma (MM), its efficacy is increased with the addition of…”
Get full text

Clinical proof of concept for a safe and effective NF‐κB‐targeting strategy in multiple myeloma by Tornatore, Laura, Capece, Daria, D'Andrea, Daniel, Begalli, Federica, Verzella, Daniela, Bennett, Jason, Acton, Gary, Campbell, Elizabeth A., Kelly, James, Tarbit, Michael, Adams, Nigel, Bannoo, Selina, Leonardi, Antonio, Sandomenico, Annamaria, Raimondo, Domenico, Ruvo, Menotti, Chambery, Angela, Oblak, Metod, Al‐Obaidi, Magda J., Kaczmarski, Richard S., Gabriel, Ian, Oakervee, Heather E., Kaiser, Martin F., Wechalekar, Ashutosh, Benjamin, Reuben, Apperley, Jane F., Auner, Holger W., Franzoso, Guido

Get full text

Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract by Joshi, Neerav M., Hassan, Sandra, Jasani, Parag, Dixon, Steve, Cavenagh, Jamie D., Oakervee, Heather E., Smith, Matthew, Agrawal, Samir A., Auer, Rebecca, de Vos, Johannes, Langmead, Louise, Rampton, David S., Gribben, John G., Taussig, David C.

Get full text

T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies by Auer, Rebecca L., MacDougall, Finlay, Oakervee, Heather E., Taussig, David, Davies, Jeff K., Syndercombe-Court, Denise, Agrawal, Samir, Cavenagh, Jamie D., Lister, T. Andrew, Gribben, John G.

“…Summary The relative merits of reduced‐intensity allogeneic stem cell transplantation (RISCT) for high‐risk indolent lymphoid malignancies are emerging,…”
Get full text

Development of original donor cell leukemia after successful engraftment from a second donor by Stevens, Jane M., Syndercombe-Court, Denise, Oakervee, Heather E., McCloskey, Daniel, Jenner, Michael J., Gribben, John G., Cavenagh, Jamie D.

Get full text

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial by Popat, Rakesh, Brown, Sarah R, Flanagan, Louise M, Hall, Andrew, Kishore, Bhuvan, Streetly, Matthew, Oakervee, Heather E, Hallam, Simon L., Smith, Matthew, Yong, Kwee L, Cook, Gordon, Cavenagh, James D.

“…Introduction: VTD is an effective regimen for patients with multiple myeloma and forms a backbone for the addition of novel agents. The MUK-six trial aimed to…”
Get full text

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma by Spicka, Ivan, Ocio, Enrique M., Oakervee, Heather E., Greil, Richard, Banh, Raymond H., Catley, Laurence, Huang, Shang-Yi, D'Rozario, James M., Dimopoulos, Meletios A., Rodríguez, José, Martinez, Sara, Extremera, Sonia, Alfaro, Vicente, Carella, Angelo Michele, Meuleman, Nathalie, Hájek, Roman, Symeonidis, Argiris, Min, Chang-Ki, Cannell, Paul, Ludwig, Heinz, Sonneveld, Pieter, Mateos, Maria V.

“…BACKGROUND: Plitidepsin, a marine-derived drug, targets the eukaryotic elongation factor 1A2e (EF1A2), a protein which is overexpressed in multiple myeloma…”
Get full text

Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3 by Tornatore, Laura, Acton, Gary, Adams, Nigel, Campbell, Elizabeth A, Kelly, James, Szydlo, Richard M, Tarbit, Mike, Bannoo, Salina, D'Andrea, Daniel, Capece, Daria, Sandomenico, Annamaria, Dyson, Julian, Leonardi, Antonio, Driessen, Christoph, Ruvo, Menotti, Anees, Ishara, Oblak, Metod, Quaid, Sheena, Al-Obaidi, Magda J, Auner, Holger, Benbenjamin, Reuben, Kaczmarski, Richard S, Kaiser, Martin F, Mehta, Atul, Oakervee, Heather E, Schey, Stephen A, Wechalekar, Ashutosh, Apperley, Jane F., Franzoso, Guido

“…The NF-κB transcription factor pathway is aberrantly activated in multiple myeloma (MM) and many other cancers, where it promotes malignancy by upregulating…”
Get full text

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC) by Popat, Rakesh, Cavenagh, James D, Owen, Roger G, Streetly, Matthew, Schey, Stephen A, Koh, Mickey, Crowe, Josephine, Quinn, Michael F., D’Sa, Shirley, Virchis, Andres, Cook, Gordon, Crawley, Charles, Pratt, Guy, Cook, Mark, Oakervee, Heather E., Counsell, Nicholas, Adedayo, Toyin, Evans, Alison, Braganca, Nivette, Smith, Paul, lyons-Lewis, Janet, Rabin, Neil, Yong, Kwee L

“…Introduction: The role of autologous stem cell transplantation (ASCT) as first line treatment for newly diagnosed patients with myeloma is currently under…”
Get full text

Differential and tumor-specific expression of CD 160 in B-cell malignancies by FARREN, Timothy W, GIUSTINIANI, Jerome, BENSUSSAN, Armand, JENNER, Michael, GRIBBEN, John G, AGRAWAL, Samir G, LIU, Feng-Ting, TSITSIKAS, Dimitris A, MACEY, Marion G, CAVENAGH, James D, OAKERVEE, Heather E, TAUSSIG, David, NEWLAND, Adrian C, CALAMINICI, Maria

Get full text

A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report by Tsitsikas, Dimitris A, Warcel-Sibony, Dana, Oakervee, Heather E., Agrawal, Samir G, Smith, Matthew, Taussig, David C, de Vos, Johannes, Stewart, Elaine, Nicholas, Hannah, Gribben, John G., Cavenagh, James D

“…Abstract 3480 Outcomes for patients with refractory or relapsed acute myeloid leukaemia (AML) are extremely poor and allogeneic haemopoietic stem cell…”
Get full text

Bortezomib, Adriamycin Dexamethasone (PAD) Combination Therapies or Patients with Relapsed or Refractory Myeloma Previously Treated with VAD or VAD like Therapy by Morris, Treen C., Drake, Mary, Kettle, Paul J., Brunton, Aishleen, Cavenagh, James D., Oakervee, Heather E., O'Dwyer, Michael, Murray, Margaret, O'Shea, Tanya, Cook, Gordon

“…Background: Although active as a single agent Bortezomib has been shown to be highly effective in combination therapy and particularly high rates of response…”
Get full text

A Phase I/II Study of Bortezomib and Low Dose Intravenous Melphalan (BM) for Relapsed Multiple Myeloma by Popat, Rakesh, Oakervee, Heather E., Foot, Nicola, Agrawal, Samir, Smith, Patricia, Craddock, Charles, Williams, Catherine, Basu, Supratik, Cavenagh, Jamie D.

“…Background: Bortezomib as a single agent has known efficacy in the treatment of relapsed multiple myeloma. The overall response rate (CR+PR+MR) was 35% in the…”
Get full text

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma by Popat, Rakesh, Oakervee, Heather E., Curry, Nicola, Foot, Nicola, Morris, Curly, Drake, Mary, Agrawal, Samir, Smith, Patricia, Schenkein, David, Esseltine, Dixie-Lee, Cavenagh, Jamie D.

“…Background: Bortezomib (formerly PS-341) has demonstrated significant activity in patients with relapsed multiple myeloma. Numerous Phase I/II studies have…”
Get full text

Development of original donor cell leukemia after successful engraftment from a second donor by Stevens, Jane M, Syndercombe-Court, Denise, Oakervee, Heather E, McCloskey, Daniel, Jenner, Michael J, Gribben, John G, Cavenagh, Jamie D

Get full text